Current Scenario of Covid-19 with Epidemiological and Phylogenetic Analysis of Pakistani Coronavirus: A Review by Altaf, Asma et al.
Journal of Bioresource Management 
Volume 7 Issue 3 Article 4 
Current Scenario of Covid-19 with Epidemiological and 
Phylogenetic Analysis of Pakistani Coronavirus: A Review 
Asma Altaf 
Department of Biochemistry and Biotechnology, The Women University, Multan, Pakistan, 
asmaaltafff@gmail.com 
Wafa Iqbal 
Department of Biochemistry and Biotechnology, The Women University, Multan, Pakistan, 
wafaiqbal950@gmail.com 
Sidra Younis 
Department of Biological Sciences, National University of Medical Sciences, Pakistan, 
sidra.younis@numspak.edu.pk 
Farah Deeba 
Department of Biochemistry and Biotechnology, The Women University, Multan, Pakistan, 
farah.9003@wum.edu.pk 
Follow this and additional works at: https://corescholar.libraries.wright.edu/jbm 
 Part of the Bioinformatics Commons, Medicine and Health Sciences Commons, and the Molecular 
Biology Commons 
Recommended Citation 
Altaf, A., Iqbal, W., Younis, S., & Deeba, F. (2020). Current Scenario of Covid-19 with Epidemiological and 
Phylogenetic Analysis of Pakistani Coronavirus: A Review, Journal of Bioresource Management, 7 (3). 
DOI: https://doi.org/10.35691/JBM.0202.0139 
ISSN: 2309-3854 online 
(Received: Jun 17, 2020; Accepted: Aug 18, 2020; Published: Sep 10, 2020) 
This Article is brought to you for free and open access by CORE Scholar. It has been accepted for inclusion in 
Journal of Bioresource Management by an authorized editor of CORE Scholar. For more information, please contact 
library-corescholar@wright.edu. 
Current Scenario of Covid-19 with Epidemiological and Phylogenetic Analysis of 
Pakistani Coronavirus: A Review 
Cover Page Footnote 
Footnote of abbreviations: CoVs, Coronaviruses; SARS, Severe Acute Respiratory Syndrome; MERS, 
Middle East Respiratory Syndrome; WHO, World Health Organization; 2019-nCoV, 2019-novel Corona 
Virus; PHEIC, Public Health Emergency of International Concern; ICTV, International Committee on 
Taxonomy of Viruses; COVID-19, Coronavirus Disease-2019; αCoV, Alpha- coronavirus; δCoV, Delta-
coronavirus; βCoV, Beta-coronavirus; γCoV, Gamma-coronavirus; R 0 , Basic Reproduction Number; UTRs, 
Untranslated Regions; S, spike; N, nucleocapsid; E, envelope; M, membrane; ACE2, Angiotensin-Converting 
Enzyme 2; HTD, Hydrophobic transmembrane Domain; LKR, Linker Region; CTD, C-Terminal Domain; NTD, 
N-Terminal Domain; NSPs, Non-structural Proteins; RTC, Replication Transcriptional Complex; APC, 
antigen presenting cells; MHC, major histocompatibility complex; HLA, Human Leukocyte antigen; CTLs, 
Cytotoxic T-Lymphocytes; ARDS, Acute Respiratory Distress Syndrome; G-CSF, Granulocyte-colony 
stimulating factor; M-CSF, macrophage colony stimulating factor; HGF, hepatocyte growth factor; NHC, 
National Health Center; PD, Parkinson disease; CHD, Coronary Heart Disease; GSK, GlaxoSmithKline; CVD, 
cardiovascular diseases; DB diabetes mellitus; HTN, hypertension; RSD, respiratory system disease; BUN, 
blood urea nitrogen. Acknowledgement: We acknowledged efforts of different countries of the World, as 
they participated in knowing about 2019-nCoV & COVID-19 as well as in reducing the impact of this 
pandemic on susceptible populations. 
© Copyrights of all the papers published in Journal of Bioresource Management are with its publisher, 
Center for Bioresource Research (CBR) Islamabad, Pakistan. This permits anyone to copy, redistribute, 
remix, transmit and adapt the work for non-commercial purposes provided the original work and source is 
appropriately cited. Journal of Bioresource Management does not grant you any other rights in relation to 
this website or the material on this website. In other words, all other rights are reserved. For the 
avoidance of doubt, you must not adapt, edit, change, transform, publish, republish, distribute, redistribute, 
broadcast, rebroadcast or show or play in public this website or the material on this website (in any form 
or media) without appropriately and conspicuously citing the original work and source or Journal of 
Bioresource Management’s prior written permission. 
This article is available in Journal of Bioresource Management: https://corescholar.libraries.wright.edu/jbm/vol7/
iss3/4 
Altaf et al. (2020). Epidemiological and Phylogenetic Analysis of Novel Corona Virus: A Review 
J Biores Manag. 7 (3): 45-65 
45 
 
CURRENT SCENARIO OF COVID-19 WITH EPIDEMIOLOGICAL AND 
PHYLOGENETIC ANALYSIS OF PAKISTANI CORONAVIRUS: A REVIEW 
 
ASMA ALTAF1, WAFA IQBAL1, SIDRA YOUNIS2, FARAH DEEBA1* 
 
1Department of Biochemistry and Biotechnology, The Women University, Multan, Pakistan 
2Department of Biological Sciences, National University of Medical Sciences, Pakistan 




A novel corona virus named as 2019 n-CoV was identified to be the actual cause of an outbreak 
of respiratory illness in Wuhan, China beginning in late December 2019. This respiratory disease 
was named as COVID-19 by WHO. There are many countries affected by COVID-19 including 
Pakistan. In this review we have provided a brief introduction of COVID-19 and discussed 
epidemiological and phylogenetic analysis of Pakistani novel corona virus strain. Our 
epidemiological analysis of data till 16th May 2020 showed rapidly increasing number of new 
cases, while at the same time a higher recovery rate than number of deaths in Pakistan. Moreover, 
phylogenetic analysis indicated that 2019-nCoV strain of Pakistan shared 100 % bootstrap value 
with various countries’ novel corona virus strains. Similarly, phylogenetic analysis was also 
conducted in comparison with SARS species to confirm our results. In this review, current 
knowledge of pathogenesis, diagnosis, treatment of COVID-19 and comorbidities which could be 
helpful in offering novel understanding and possible therapeutic targets for fighting against the 
COVID-19 infection are discussed. 
  




Coronaviruses (CoVs) are the part of 
the family Coronaviridae with subfamily and 
order Orthocoronavirinae and Nidovirales 
(Banerjee et al., 2019). CoVs are familiar 
human pathogens, with an association to mild 
acute respiratory illnesses known as the 
common cold (Wilson et al., 2020). CoVs 
mainly cause enzootic infections in birds and 
mammals but prior outbreaks of CoVs in the 
last decades, including the Severe Acute 
Respiratory Syndrome (SARS)-CoV in 2002 
and the Middle East Respiratory Syndrome 
(MERS)-CoV in 2012, have confirmed the 
deadliness of CoVs when they infect humans 
by crossing species barrier (Bogoch et al., 
2020). A group of patients, with a primary 
diagnosis of pneumonia of ambiguous origin, 
were admitted to hospitals in late December 
2019. Several of the early patients visited a 
wet seafood and animal market in Wuhan, 
Hubei province, China (Lu et al., 2020a). 
Successive virus isolations from human 
patients and their molecular analysis revealed 
that the disease-causing agent was a novel 
coronavirus, first named as 2019-nCoV.  The 
WHO (World Health Organization) revealed 
the outburst of a Public Health Emergency of 
International Concern (PHEIC) on January 
30, 2020. Another name SARS-CoV-2 was 
suggested by a study group of the 
International Committee on Taxonomy of 
Viruses (ICTV) based on taxonomy 
phylogeny, and established practice on 
February 11, 2020, afterwards this disease 
was renamed by WHO as COVID-19 on 
February 12, 2020. This review is focused on 
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up to date aspects of COVID-19 and 
epidemiological and phylogenetic analysis of 




CoVs have mainly four genera 
namely, αCoV (alpha coronavirus), δCoV 
(Deltacoronavirus), βCoV (Betacoronavirus) 
and γCoV (Gammacoronavirus). Their 
evolutionary investigations indicated that 
gene sources of αCoV and βCoVs were bats 
and rodents while avian species were the 
gene sources of many δCoV and γCoVs. 
These viruses gradually crossed species 
barrier and have become evident human 
pathogens (Chan et al., 2020a). The first 
complete genome of the novel β genus 
coronavirus (later named SARS-CoV-2) was 
discovered in a patient from Wuhan by taking 
broncho alveolar lavage fluid as a sample on 
January 3, 2020 (Wu et al., 2020b). The 
experimental report declared that the virus 
had 88 % sequence similarity with two bat-
derived SARS (severe acute respiratory 
syndrome) like CoVs, but recognizably 
different in nature from SARS-CoV (Lu et 
al., 2020b). On the support of present data, it 
appears that COVID-19 might be originally 
hosted by bats, and it is a possibility that it 
was transmitted to humans through pangolins  
(Lam et al., 2020) or various other wild 
animals that were being sold at Huanan 
seafood market and successive spread 
occured through human to human 
transmission  (Zu et al., 2020).  
 
EPIDEMIOLOGY AND PREVALENCE 
 
On 31 December 2019, the WHO 
China Country Office was informed of cases 
of pneumonia with unknown etiology, 
detected in Wuhan City, Hubei Province of 
China. From 31 December 2019 through 3 
January 2020, a total of 44 case-patients with 
pneumonia of unknown etiology were 
reported to WHO by the national authorities 
in China. During this reported period, the 
causal agent was not identified. Data from 20 
January 2020 to 8 April 2020 was observed. 
On 20 January 2020, 278 confirmed cased of 
2019-nCoV were reported in China out of 
282 total reported cases. While on 8 April 
2020, 1,353,361 confirmed cases (73,639 
new) with 79,235 deaths (6,695 new) were 
reported globally and 83,157 confirmed (86 
new) cases and 3,342 deaths (2 new) were 
reported in China, (“Coronavirus disease 
2019 (COVID-19) Situation Report – 79”, 
2020). Data reported on 16th May, 2020 of 
most affected countries is represented in the 
form of graph (Figure 1A). It consists of total 
confirmed cases (affected individuals), 
deaths and recovered patients of different 
countries from onset of the disease till May 
16, 2020.  
Data of COVID-19 cases in main 
areas (including five provinces) of Pakistan is 
depicted in the form of graph (Figure 1B). As 
is shown in the graph, the highest total 
confirmed cases were in Sindh, while lowest 
numbers of cases were present in Azad 
Jammu Kashmir (AJK). Total deaths and 
total recoveries in Pakistan, are presented in 
the form of graph (Figure 1C). Data till 16th 
May, 2020 showed higher recovery rate than 
number of deaths as presented in graph. 
Numerical data of newly identified cases on 
daily basis versus newly recovered patients is 
presented in graphical form as shown in 
graph (Figure 1D). Number of new cases was 
increasing on a daily basis and was greater 
than that of recovered individuals as 
indicated in the graph. Data of daily new 
COVID-19 cases in Pakistan is presented in 
graph (Figure 1E).  
R0 (Basic Reproduction Number) is 
the mean amount of secondary infection that 
patient may develop in an entirely susceptible 
population without any intervention (Remais, 
2010). Estimation of R0 of 2019-nCoV (2.0-
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3.30) indicated that 2019-nCoV has high 
transmissibility as compared to other CoVs. 
 
 
Figure 1: (A) Graphs of COVID-19 cases of most suffered countries, (B) total cases of Pakistan till May 16, 
2020, (C) total deaths versus total recoveries in Pakistan, (D) new cases versus newly recovered cases in 
Pakistan, (E) new cases of COVID-19 reported in Pakistan on daily basis.  
 
PHYLOGENETIC ANALYSIS 
Spike protein analysis of 2019-nCOV from 
different countries with Pakistani novel 
corona virus (n-CoV) strains 
Here we aimed to reveal evolutionary 
position of Pakistani n-CoV strain with 
respect to n-CoV strains of different 
countries based on spike (S) glycoprotein 
gene analysis. For phylogenetic analysis the 
dataset used included (n=17) S glycoprotein 
gene sequences of current epidemic from 
different countries, plus (n=2) n-CoV strains 
from Pakistan (Gilgit, KPK). These 
sequences were retrieved from NCBI 
database 
(http://www.ncbi.nlm.nih.gov/genbank/). 
Evolutionary examination was conducted in 
MEGA 7.0 version applying ML (maximum 
likelihood) method based General Time. The 
tree was constructed to scale, with the branch 
lengths in same units as those of evolutionary 
distances used to deduce phylogenetic-tree 
(Zuckerkandl and Pauling, 1965). 
This analysis suggests that novel 
coronavirus S protein sequences from Gilgit 
and KPK share 100% bootstrap value with n-
CoV protein sequences from various 
countries which means that COVID-19 in 
Pakistan was caused by the same n-CoV 
which targeted other countries (Figure 2A). 
Emergence of this virus in Pakistan might be 
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due to the tourists visiting, which were 
already infected or by people which were 
deported by corona infected countries. Thus, 
these infected people spread the disease in 
natives.  
 
Phylogenetic analysis of Pakistani n-CoV 
strains V/S previously known SARS species 
spike (S)-gene sequence 
 
We further broadened the analysis by 
targeting the S glycoprotein gene of the CoVs 
from human SARS, bat-like CoVs, animal-
origin CoVs together with MERSV and the 
current outbreak of n-CoV in Pakistan. These 
sequences were retrieved from NCBI 
(http://www.ncbi.nlm.nih.gov/genbank/) 
database. Evolutionary examination was 
conducted in MEGA 7.0 version applying 
ML (maximum likelihood) method based 
General Time. In this phylogenetic analysis, 
Pakistani nCoV strains clustered in a 
monophyletic clade. Our analysis indicates 
that two bat SARS-like CoVs (Bat-SL-
RsSHC014, and Rs3367) and two β-CoVs 
(BtRs-BetaCoV/YN2018C and BtRs-
BetaCoV/YN2018D) are sharing 100% 
bootstrap support with Pakistani 2019-nCoV 
isolates. Our analysis confirms that this is 
same coronavirus strain that infected other 
countries as represented in Figure 2B. 
However, spread of COVID-19 is less severe 
in Pakistan as compared to other countries 
according to the data till 9 April. One reason 
of this less prevalence could be strong 
immunity of Pakistani but further research is 
needed to confirm this fact. 
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Figure 2 Phylogenetic analysis of Pakistani n-CoV isolates (A) Phylogenetic analysis of spike glycoprotein gene sequences of 2019-nCoV strains (17 
different countries and 2 Pakistani).The solid-red circles are for n-CoV isolates from Pakistan.(B) Phylogenetic analysis of spike glycoprotein gene 
sequences of 2019-nCoV strains (17 different SARS species, 2 Pakistani).The solid-red circles are for n-CoV isolates from Pakistan.
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ORGANIZATION OF GENOME 
2019-nCov has single stranded RNA 
genome of 29891 bases encoding 9860 amino 
acids. Novel corona virus genome, similar to 
other βCoVs, has two UTRs (untranslated 
regions) and a polyprotein encoding single 
long open reading frame. The G+C content 
was found to be 38 %. Hemagglutinin-
esterase gene which is primarily present in 
lineage A β-CoVs is absent in 2019-nCoV 
and its genome is organized in sequence of 
5′-replicase (orf/ab)- proteins of structural 
nature, nucleocapsid (N)-Envelope (E)-Spike 
(S)-Membrane (M)-3′. Notably, orf3b 
encodes a completely new short protein. 
Moreover, new orf8 probably encodes a 
secreted protein with anα-helix, following 
with a β-sheet(s) consisting six strands as 
shown in Figure 3A. 
Spike glycoprotein 
Spike glycoprotein consists of two 
subunits S1 and S2. The components in these 
subunits are shown in Figure 3B. It was found 
that S2 subunit of novel coronavirus is 
largely reserved. It is 99% identical to human 
SARS-CoV and two bat SARS-like CoVs 
(ZC45 and SL-CoV ZXC21). Coronaviral 
proteins called spike (S) binds to ACE2 
(angiotensin-converting enzyme 2) receptor 
and initiates successive fusion between the 
host cell membrane and envelope and in turn 
help in viral entry into host cell (Kirchdoerfer 
et al., 2016). 
 M protein  
The most abundant protein present in 
virion particle is the M protein and it provides 
particular shape to viral envelope (Neuman et 
al., 2011). M proteins of CoVs are very much 
diverse, M-M interaction is involved in 
maintaining viral scaffold (Arndt et al., 
2010). In contrast to SARS-CoV the M 
protein of 2019-nCoV does not have any kind 
of amino acid substitution (Wu et al., 
2020a).   
E protein  
Among the major structural proteins, 
E protein is the most mysterious and smallest. 
It plays a multi-functional role in assembly, 
pathogenesis and release of virus (Nieto-
Torres et al., 2014). Deletion or inactivation 
of this protein cause changes in tropism and 
morphology which in turn lead to variation in 
virulence of coronavirus (DeDiego et al., 
2007). The E protein of 2019-nCoV presents 
a comparable amino acid constitution without 
any type of substitution (Wu et al., 2020a). 
N protein 
Multi-purpose N protein of 
coronavirus has role in increasing 
transcription efficiency of virus, formation of 
complex with viral genome and aids M 
protein interaction required for virion 
assembly (Chang et al., 2006). It consists of 
three recognizably different and highly 
conserved domains which are linker region 
(LKR) or RNA-binding domain and a (CTD) 
C-terminal domain (McBride et al., 2014). 
The N protein of 2019-nCoV, in contrast with 
SARS-CoV, has five amino acid mutations. 
Where two are present in IDR (intrinsically 
dispersed region; 26 and 25 positions), and 
other in LKR (217 position), NTD (103 
position) and CTD (334 position). 
NSPs and accessory proteins  
Besides the crucial structural 
proteins, 2019-nCoV genome also contains 8 
accessory proteins (3a, 7a, 9b, 3a, 8b, p6 and 
orf14) and nsp 12-16, 15 nsps, nsp1-nsp10. 
2019-nCoV genome does not contain longer 
8b and 8a proteins in comparison with SARS-
CoV. Matrix, envelope, nsp13, nsp7 or 
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accessory proteins 8b and p6 have not been 
found with any amino acid substitution with 
respect to CoVs as shown in Figure 3C (Wu 
et al., 2020a). 
 
 
Figure 3: (A) Organization of βcoronavirus. The genome is composed of ORF (open reading frame), 1ab (Steel 
blue box), nsp ( non-structural proteins), structural proteins including envelope (dark khaki box), spike (Slate 
gray box), membrane (chocolate box), accessory proteins (Corn flower blue box) such as orf 9b, 7b, 7a, 8, 3 and 
6, similarly nucleocapsid proteins (dark slate blue box) and 5'-UTR in the 2019-n CoV. Example of lineages is 
from A to D. The length of orfs and nsps are not drawn to scale. (B) Components of S1 and S2 subunits. S1 
subunit has S-peptide (single peptide), RBD (receptor binding domain), NTD (N-terminal domain) while S2 
subunit has F-peptide (fusion peptide), HP (heptad repeat), CM (cytoplasmic domain), TM (transmembrane 
domain). (C) Structure of 2019-nCoV. “S” (spike glycoprotein), “M” (membrane protein), “N” (nucleocapsid 
protein), “E” (envelope protein), “ssRNA” (single stranded positive sense RNA). 
 
MOLECULAR COMPARISON 
BETWEEN ACE2 RECEPTORS OF 
HUMAN AND ANIMAL SPECIES 
The recognition of residues of contact 
between human ACE2 and 2019-nCoV 
receptor binding domain permit estimation of 
whether 2019-nCoV is able to infect other 
species. To evaluate this Sun et al., (2020) 
aligned amino acid sequences of all available 
ACE2 with human ACE. They focused on N-
glycosylation of motifs near the binding site, 
as they may affect attachment of S (Sun et al., 
2020). The molecular differences they found 
are given in Table 1. Particularly, binding of 
S from SARS-CoV to rat is prevented by 
glycosylation of residue 82 (Li et al., 2005). 
Further Sun et al., (2020) found that amino 
acid differences in ACE2 affect binding of 
2019-nCoV in various species. Studies of S 
binding site of ACE2 from various species 
disclose that ten and nine amino acid 
differences are found in rodents (mouse and 
rat respectively), eleven in chicken, and only 
three are present in cats as compared with 
ACE2 of human. ACE2 of human is identical 
to ACE2 from chimpanzees and macaque. 
So, these amino acid and glycosylation 
differences make these animals reservoirs for 
2019-n CoV. A structure model examination 
shows that 2019-nCoV binds with ACE2 of 
host with above 10 folds higher affinity than 
SARS-CoV (Wrapp et al., 2020). These 
findings explain the faster transmission 
ability of 2019-n CoV in humans than SARS-
CoV, and this may be reason of much higher 
confirmed COVID-19 cases than SARS-CoV 
infection. Taking into consideration the high 
affinity of 2019-nCoV binding with ACE2, 
soluble ACE2 might be a possible approach 
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for treatment of COVID-19 treatment. 
Patients with COVID-19 exhibit similar 
clinical signs and symptoms with those of 
SARS-CoV and MERS-CoV infections 
(Huang et al., 2020). Since pathogenesis of 
COVID-19 is not properly understood by 
scientist, the somewhat similar mechanism of 
MERS-CoV and SARS-CoV can give us 
much information about pathogenesis of 
2019-nCoV infection to facilitate our 
understanding about COVID-19. 
 
Table 1: Glycosylation differences of ACE motifs in different species. 
Species Glycosylation Sites Sites at which glycosylation does 
not occur 
Human N53, N90, N322*  
Mouse, pig, raccoon, fox, chicken, N. 
procyonoides, ferret, E. telfairi and civet 
 N90 
Sheep, rat, cattle, pangolin, E. telfairi, 
mouse 
 N322 
Additional glycosylation motif in this region of ACE2 in some species  
Chicken L79  
Rat, Rhinolophus sinicus, and pangolin M82  
*N322 common in all species 
 
PATHOGENESIS OF THE 
CORONAVIRUS 
 Entry and replication of coronavirus 
Cell receptors, ACE2, for 2019-nCoV 
are found in lower respiratory tract of humans 
(Jia et al., 2005). S-glycoprotein on the 
surface of virion is capable of attachment to 
these (ACE2) receptors (Tortorici and 
Veesler, 2019). The entrance of SARS-CoV 
into the cell was primarily recognized to be 
accomplished by face to face fusion between 
the plasma membrane and virus. Belouzard et 
al. (2009) discovered that membrane fusion 
and viral infectivity of SARS-CoV is 
mediated by critical proteolytic cleavage 
event at S2' position of ‘S- protein’. In 
addition to membrane fusion clathrin-
independent and dependent endocytosis 
mediated entry of SARS-CoV has also been 
observed (Wang et al., 2008). After the virus 
entry into the cell, the viral genome is 
released into the cytoplasm and is translated 
into two (pp1a, pp1ab) polyproteins (de 
Wilde et al., 2017), which encodes NTP (non-
structural proteins) and form RTC 
(replication transcriptional complex) 
(Sawicki and Sawicki, 2005). Newly 
synthesized envelope glycoproteins, genomic 
RNA and nucleocapsid proteins arrange and 
from viral particle buds. At the end, viruses 
are released by the fusion of these virus 
containing vesicles with plasma membrane 
(de Wit et al., 2016). 
Antigen presentation during coronavirus 
infection 
The direct infection of T cells and 
macrophages by SARS-CoV has been 
reported, but it is still unknown whether 
2019-nCoV infects immune cells 
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(Prompetchara et al., 2020). In the central 
part of the body’s anti-viral immunity, after 
the entry of virus in the cells, its antigen 
would be presented to APC (antigen 
presenting cells). MHC (major 
histocompatibility complex) or HLA (human 
leukocyte antigen) in humans presents the 
antigenic peptides, which are then recognized 
by the CTLs (cytotoxic T lymphocytes). 
Thus, comprehension of 2019-nCoV antigen 
presentation will help our understanding of 
COVID-19 pathogenesis.  
Humoral and cellular immunity 
Presentation of antigen then activates 
the body’s cellular and humoral immunity, 
virus-specific B and T cells are responsible 
for this immunity. IgG and IgM production 
occurs against SARS-CoV virus, similar to 
some common acute viral infection. IgG 
antibodies may principally play protective 
role, as they can last for longer time, while 
SARS-specific IgM antibodies vanish at the 
end of week 12 (Li et al., 2003). SARS-
specific IgG antibodies are mainly N-specific 
and S-specific antibodies. A recent report 
showed that the number of CD8+ and CD4+ 
T-cells was remarkably reduced in peripheral  
blood of 2019-nCoV  infected patients, 
although its status is  too much activation, as 
revealed by high fraction of CD38 (CD8 39.4 
%) and HLA-DR (CD4 3.47 %) double-
positive proportions (Xu et al., 2020). In the 
same way in patients with SARS-CoV, the 
acute phase response is related with a serious 
decrease of CD8+ and CD4+ T-cells. In 
SARS-CoV recovered individuals, even if 
there is no antigen present, the memory T-
cells will remain present for four years and 
can carry out T-cell multiplication, 
production of IFN-γ and DTH response (Fan 
et al., 2009).The particular CD8+ T cells also 
exhibit a similar effect on MERS-CoV 
clearance in mice. These previous findings 
may give valuable details for the rational 
design of vaccines against 2019-nCoV.  
COVID-19 and Cytokine storm  
In case of CoVs infection (SARS-
CoV, 2019-nCoV and MERS-CoV) acute 
respiratory distress syndrome (ARDS) is the 
usual immunopathological event (Xu et al., 
2020). The uncontrolled deadly 
inflammatory response is produced due to 
release of a very large amount of IL-16, IL-
18, IL-12, IL-33, IFN-γ,IL-1β, TNF-β, IFN-
α and TGFα, etc. (pro-inflammatory 
cytokines) and CCL3, CXCL8, CXCL10, 
CCL2, CCL5, CXCL9 etc. (chemokines) in 
SARS-CoV infection, by immune effector 
cells (Williams and Chambers, 2014). Some 
plasma chemokines and cytokines were also 
found to be increased in case of COVID-19 
patients, these include different types of 
interleukin (IL-2, IL-1, IL-10, IL-7, IL-17, 
IL-13, IL-12, IL-1), G-CSF (Granulocyte-
colony stimulating factor) M-CSF 
(macrophage colony stimulating factor), 
HGF (hepatocyte growth factor), MCP-1α, 
MCP-1,IP-10, TNF-α and IFN-γ (Chen et al., 
2020). Accumulatively, the virus particles 
occupy the respiratory mucosa at first and 
then infect other cells of the body, they 
initiate the synthesis of cytokine storm in the 
body and a series of immune responses as 
shown in Figure 4. This cytokine storm will 
activate an intense attack to the body by 
immune system causing multiple organ 
failure and will at the end lead to the death of 
severe cases of 2019-nCoV infection (Xu et 
al., 2020). 
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Figure 4: Pathogenesis of 2019-n-CoV; 2019-nCoV entry and replication. 1: Attachment of virus with ACE2 
receptors. 2: Vesicle formation. 3: Virus entry in cell. 4: Replication of genome. 5: Newly synthesized viral 
particle buds. 6: Released viral particles, Antigen Presentation MP (macrophage particles), DC (dendritic 
cells), EC (epithelial cells), APC (antigen presenting cells), CK (cytokines),Cellular immunity CK (cytokines), 
TC (T-cells/lymphocytes), Humoral immunity PC (plasma cells), M-BC (memory B-cells), Th2-C (helper -T 
cells). 
 
Incubation Period of 2019-nCoV 
The average incubation period of 5.2 
days was reported by a study of initial 
transmission kinetics of 2019-nCo (Backer et 
al., 2020). In a later study, performed based 
on appearance of symptoms and travel 
history of 88 confirmed patients, a 
comparable average incubation period of 6.4 
days was described. A unique case was 
reported having an incubation period as long 
as 19 days (Bai et al., 2020). Particularly, a 
long incubation time indicates 
acclimatization in screening and control 
policies (Jiang et al., 2020). In the recent 
guidelines provided by Chinese health 
authorities, a mean incubation period of 7 
days, varying from 2-14 days was declared. 
 
 
Transmission of Coronavirus 
Two main transmissions of 2019-
nCoV are zoonotic (via contact with animals) 
and anthroponotic (via direct or indirect 
contact with affected individual) 
transmissions. Many wild and tame animals, 
comprising cats, cattle and bats can function 
as host for different coronaviruses. Snakes 
and pangolins at untamed animal stores were 
seemingly to be intermediary hosts of 2019-
nCoV, as shown by latest studies however 
evidence of human to human viral 
transmission has also been reported (Liu et 
al., 2020). Three main, human to human 
routes for transmission of COVID-19 include 
direct transmission (respiratory droplets), and 
indirect routes of transmission (fomites and 
aerosols). Contact transmission can occur 
when a person comes in contact with an 
object or a surface, which is already 
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contaminated with virus and thereafter 
touches his/her nose, eyes or mouth 
(transmission through fomites). Respiratory 
droplets are formed when an infected 
individual sneezes or coughs for distances 
longer than six feet; these droplets travel in 
the form of aerosols. Digestive system, as 
another possible route of transmission of 
2019-nCoV was described by another study 
in which it was observed that ACE2 was 
immensely expressed in absorptive cells of 
alimentary tract from colon and ileum (Zhang 






Clinical and laboratory findings 
 After an approximate incubation time 
of 5.2 days, symptoms of 2019-nCoV viral 
infection become visible (Li et al., 2020a). 
Guidelines for treatment and diagnosis of 
2019-nCoV (Wang et al., 2020b) are made 
and updated by NHC (National Health 
Center) of China, on the basis of broad range 
of connected ideas of disease severity. Based 
on the severity of associated symptoms, 
COVID-19 is now organized into four levels: 
critical, severe, moderate and mild. Their 
associated clinical and laboratory features are 
described in Table 2. Cases ending in death 
were chiefly middle-aged and old-age 
patients already having any other disease(s) 
such as diabetes, PD (Parkinson disease), 
CHD (Coronary Heart Disease), cirrhosis, 
hypertension or tumor surgery (Li et al., 
2020b). 
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Table 2: Clinical & Laboratory findings of COVID-19. 
Clinical Feature Laboratory features 
Complicated dyspnea, myalgia, cough, pneumonia & 
fever are frequently reported systems, while diarrhea is 
uncommon. 
Viral load decreased total lymphocytes, prolonged 
APTTa&PTb, and increased level of creatinine, ALTc, 
ASTd, blood urea, thrombocytopenia, increased cTnIe& 
angiotensin II, decreased ALBf. 
Mild patients: mild fatigue, no pneumonia and low 
fever. 
Most patients: increased ESRg, & CRPh with normal 
procalcitonin. 
Moderate patients: radiographic features, fever and 
respiratory symptoms. 
Severe cases: Elevated D-dimer, FDPi, decreased 
lymphocytes in peripheral blood. 
Severe patients: hypoxemia/dyspnea one week after the 
onset of disease. 
Patients of ICU: elevated TNFαj and other 
inflammatory cytokines.  
Critical patients: ARDSk, shock, multiple organ failure. 
Anorexia, dyspnea and abdominal pain were also 
common. 
Non-survivors: elevated blood urea, D-dimer, 
creatinine and neutrophil count. 
aAPTT: Activated partial thromboplastin time, b PT: Prothrombin time,cALT: Alanine transaminase, d AST: Aspartate 
transaminase, e cTnI: Cardiac troponin I, f ALB: Albumin, g ESR: Erythrocyte sedimentation rate, h CRP: C-reactive 




ADVANCEMENT IN DIAGNOSIS OF COVID-19 
 
Immediate and precise diagnosis of COVID-19 is critical to control outset in hospitals or 
in any community (To et al., 2020). Auxiliary assessments like epidemiological history, 
understanding of clinical symptoms and radiographic characteristics are essential for diagnosing 
2019-nCoV and associated irregular symptoms (Li et al., 2020c). Description of different 
techniques is given in Table 3. 





Nucleic acid detection methods 
NGS and virus blood culture are authorized methods 
but cannot be used because of high price & 
equipment dependency (Zhou et al., 2020). 
RT-qPCR is most ordinary, efficient and simple 
technique gives 50-79% sensitivity (Yam et al., 
2003) also gives *FNR. 
RT-LAMP is very precise, has sensitivity similar 
with rRT-PCR & is used for detection of MERS-CoV 
(Huang et al., 2018). 
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From three RT-PCR assays, RdRp/helicase method 
is highly reactive& and is regarded as specific and 
recommended assay (Chan et al., 2020b). 
Cobas 6800 with a good systematic operation takes 
less time & offers authentic results (Eigner et al., 
2019). 
 
Computerized Tomography (CT) Scans 
Used in combination with rRT-PCR particularly for 
early detection & evaluation of severeness of disease 
(Pan et al., 2020). However, contain inadequacies 
e.g. being indistinct from pneumonia caused by other 
viruses & hysteresis of unusual CT imaging. 
 
Enzyme Linked Immunosorbent Assay (ELISA) 
Exhibit higher diagnostic rates than other techniques 
& is highly suggested method (Wang et al., 2020a). 
It has fast turnaround time & comparatively low 
costs. A warning is that it can give **FPR, because 
of conservative N-protein of 2019-nCoV. 
*False negative result ** False positive result 
ADVANCEMENT IN TREATMENT 
Drugs and herbal treatment 
Treatment of COVID-19 by using different drugs and herbal plants or their extracts is summarized 
in Table 4. 
Table 4 Different drugs and herbal plants used in treatment of COVID-19. 















respiratory canal, and 
represses synthesis of 
IL 4, 5 and TNF-α. 
A study shows that 
respiratory status in 
patients of COVID-
19 can be improved 
by this drug. 
It contains less 
systemic side effects 
& is virtuous for 
additional study in 
clinical trials. 




operative pro-drugs)  
Reduces levels of IL-
8, 1B, 6, 12, TNF-α, 
interferon gamma, 
neutrophil count & 
ROS, CRP. 
Can serve as 
possible candidate 
to prevent most of 
immuno-
pathological 
The need is to do 
clinical examination 
with huge sample 
size to find out its 
(Bayraktar et al., 
2005) 
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Used to cure bacterial 
infections, but already 
efficient against 
viruses, acts on the 
initial step of virus life 
cycle. 
Zhou et al reported 
that it stops 
liberation of viral 
genomic RNA & the 
protraction of virus 
replication occurs. 
Further analysis 
about its effect 
against COVID-19 is 
needed & it suggests 
that this drug can 
serve as potential 











fibrosis and lung 
injury. 
 Clinical condition, 
absolute 
lymphocyte value 
and cytokine level 
were improved by a 




exudation was also 
obtained. 
It may be used as 
adjuvant treatment 
strategy for 
potentially fatal viral 
disease. 




Also effective in 
removing 
nasopharyngeal 
carriage of virus in 3-
6 days 
A clinical trial 
performed by P 
Gautret et al. 
showed that all 
patients receiving 
these drugs were 
cured at the day 6 of 
post inclusion 
These findings need 
further research to 
check whether this 
combination is 
effective in severe 
cases 




bioactive agent in 
vitro) 
Prevent binding of 
virus to cell surface, 
may interfere at the 
budding step of the 
replication cycle of 







an effective drug 
against COVID-19, 
presently ten 
clinical trials are 
trying to test the 
effectiveness of this 
drug as an anti-
COVID-19 therapy 
A survey study is 
needed to check the 
adverse effects of 
therapy done by 
using this drug 
(Randolph et al., 
1990) 
Indian herbal plants 




Protease inhibitors of 
2019-nCoV. 
In a study by 
Ambrish K. 
Srivastava et al. the 
inhibition capability 
of their extracts was 
found. 
Can serve as effective 
therapeutic agents 
against COVID-19 
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Halt the activity of 
SARS 3CLpro 
enzyme, also halt 
helicase protein of 
SARS-CoV namely, 
nsP13 in laboratory by 
disturbing ATPase 
activity. 
Inhibition of lung 
inflammation & 
reduced levels of 
cytokines along 
with IL β and 6 is 
obtained by the 
injection of Shen 
Fu, as described by 
Wang, et al. 
Convincing evidence 
is that herbal 
products of some 
traditional Chinese 
medicines or their 
parts possess strong 
immuno-suppressive 
impacts. 
(Chen et al., 
2002) 
Treatment using antibodies and Vaccines 
Monoclonal antibodies target 
susceptible sites on the surface of viral 
proteins, first reported monoclonal antibody 
that reacted with 2019-nCoV was 47D11. In 
a latest report, use of convalescent plasma 
was identified as a possible treatment for 
COVID-19 (Zhang et al., 2020). A meta-
analysis from previous study revealed a 
decrease in death rate by receiving diverse 
dosage of convalescent plasma in patients 
having serious respiratory infections, with no 
unfavorable events or problems after 
treatment (Mair-Jenkins et al., 2015). One 
practicable explanation for the efficiency of 
convalescent plasma therapy is that 
immunoglobulins from convalescent plasma 
could reduce viraemia. Hence, it can be 
beneficial to test the security and 
effectiveness of convalescent plasma 
transfusion in COVID-19 infected patients. 
Antigen S has been involved in various kinds 
of vaccines against contamination by CoVs 
(Yu et al., 2020). Moderna declared the 
commencement of phase#1 testing of mRNA 
vaccine-1273 on 16 March. On 24 February 
2020, Moderna declared the release of first 
batch of this vaccine for use in humans 
against 2019-nCoV (Anon., 2020). 
GlaxoSmithKline (GSK) declared a 
co-operation with a Chinese company to 
assess COVID-19 vaccine. This participation 
was able to produce COVID-19 S Trimer 
vaccine with adjuvant system. 
Us20060039926 (patent) application 
revealed live attenuated torovirus or 
coronavirus vaccines. Interestingly, GLS-
5300 (INO-4700) is already under phase#1 
clinical analysis. The vaccine was well-
tolerated, inducing immunoglobulin response 
in 94% of patients after 3 injections. Its 
immune reactions were not dependent on 
dose and it was effective through 1 year of 
follow-up (Modjarrad et al., 2019). It was 
suggested by a research, that BCG vaccine 
seemed to significantly decrease number of 
deaths caused by COVID-19 (Miller et al., 
2020). It is necessary to synthesize safe and 
efficacious vaccines to restrain COVID-19 
epidemic, eradicate its spread and eventually 
stop its recurrence in future. 
COVID-19 AND COMORBIDITIES 
Comorbidities are risk factors for 
2019-nCoV infection. Diseases like CVD 
(cardiovascular diseases), DB (diabetes 
mellitus), HTN (hypertension), RSD 
(respiratory system disease) and their 
susceptibility states, might be connected to 
the generation and development of COVID-
19. These metabolic diseases can impair the 
function of macrophages and lymphocytes 
making a person more vulnerable to 
complication of other diseases. In a research, 
among patients having serious symptoms of 
COVID-19, 25%, 44% and 58% people had 
heart diseases, arrhythmia and hypertension 
respectively (Bai et al., 2020). In accordance 
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with mortality data provided by NHC, 17% 
patients with COVID-19 had history of CHD, 
while 35% patients had hypertension. 
Similarly, it has been reported that 
patients with T2DM (type-2 diabetes 
mellitus) and metabolic syndromes when 
they were infected with COVID-19, had 
increased chances of death by up to ten-times 
(Yang et al., 2006). During the course of 
SARS in 2003, multiple organ involvement 
such as gastrointestinal tract, liver and kidney 
was reported. Recently, quite similar multi-
organ involvement has been documented in 
COVID-19 patients. It has been reported that 
13.1% and 14.4% patients in the study had 
impaired BUN (blood urea nitrogen) and 
creatinine levels (Cheng et al., 2020). 
Moreover, in a recent analysis done by China 
(Sidaway, 2020), 18 out of 1590 COVID-19 
infected individuals had a history of cancer. 
The available evidence is insufficient, but it 
proposes that symptoms of COVID-19 are 
very likely more critical in patients having 
cancer as compared to those without. Hence, 
we may assume that underlying diseases like 
DB, HTN, CVD, RSD and cancer may be risk 
factors for severe patients of COVID-19 in 
comparison with non-severe patients.   
CONCLUSION 
This review holistically explains the 
current research done in response to outbreak 
of COVID-19 and 2019-nCoV, mainly 
focusing on the phylogenetic and 
epidemiological analysis of Pakistani 
coronavirus. Our epidemiological analysis of 
available data showed less prevalence rate of 
COVID-19 along with less mortality rate of 
affected individuals in Pakistan as compared 
to other countries affected with COVID-19. 
Phylogenetic analysis confirmed that 
Pakistani n-CoV strain resembled with bat 
SARS-like corona virus. Epidemiological 
history, clinical presentation, and few 
auxiliary assessments like ELISA, POCT of 
IgG and IgM, detection of nucleic acid, blood 
culturing and CT scans are methods for the 
clinical diagnosis of COVID-19. Until now, 
specific vaccines or anti-viral medicines 
against COVID-19 do not exist for potential 
cure of humans. The only alternative 
available is utilization of broad spectrum 
anti-viral medicines and other drugs to 
reduce associated symptoms like respiratory 
issues, inflammation etc. It is concluded that 
COVID-19 associated symptoms and 
mortality may be reduced mainly by adapting 
preventive measures as up to now no specific 
vaccine is available for its cure. 
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